DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Pascal Soriot - 1 AstraZeneca’s - 1 Ivan Menezes - 1 Debra Crew - 1 Soriot - 1 Susan Galbraith - 1 David Fredrickson - 1 Luke Miels - 1
Top related locs:
AstraZeneca’s Swedish
Top related orgs:
Pfizer - 1 pharma - 1 Novartis - 1 Sanofi - 1 GSK - 1 AstraZeneca - 1 Diageo - 1 Thomson - 1

Search resuls for: "Soriot’s"


2 mentions found


☆ AstraZeneca succession sickness demands urgent fix
  + stars: | 2023-09-15 | by ( Aimee Donnellan | ) www.reuters.com   time to read: +3 min
LONDON, Sept 15 (Reuters Breakingviews) - Can a CEO be worth $9 billion? That’s the question posed by the 4% fall in AstraZeneca’s (AZN.L) shares following an article stating boss Pascal Soriot may soon resign. The company has played down the report, and its stock has recovered, but the episode highlights its uncertain position were 64-year-old Soriot to leave. Without a clear succession plan, investors should prepare for further swings. Small wonder investors and analysts wonder whether AstraZeneca will be able to find a successor capable of replicating his success.
Persons: Pascal Soriot, AstraZeneca’s, Ivan Menezes, Debra Crew, Soriot, Susan Galbraith, David Fredrickson, Luke Miels, Soriot’s, Neil Unmack, Streisand Neto Organizations: Reuters, Pfizer, pharma, Novartis, Sanofi, GSK, AstraZeneca, Diageo, Thomson Locations: AstraZeneca’s, Swedish
☆ AstraZeneca’s new deal is smarter than it looks
  + stars: | 2023-01-09 | by ( ) www.reuters.com   time to read: +2 min
LONDON, Jan 9 (Reuters Breakingviews) - On the face of it, Pascal Soriot’s new deal ought to raise his shareholders’ blood pressure. The boss of $221 billion pharma giant AstraZeneca (AZN.L) has agreed to buy CinCor Pharma (CINC.O) for up to $1.8 billion. Yet paying $26 in cash per CinCor share and an extra $10 per share if a key drug is submitted for regulatory approval represents a 206% bump to CinCor’s closing share price on Friday. The pharma industry has a war chest of over half a trillion dollars to splurge on knock-down biotech stocks this year. If the next trial goes better, Astra’s deal may not look so toppy.
0 next >>
Total: 2